The scRN-Seq analysis from the HPA revealed that ORMDL2 was highly expressed in TAMs and glioma stem-like cells (GSCs), two major contributors to immune evasion and therapeutic resistance in GBM. Here, ORMDL2 is linked to central nervous system cancer.